Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a clinical-stage biopharmaceutical company, today announced that the underwriters of the previously announced public offering of its common shares have exercised in full their option to purchase an additional 600,000 common shares, consisting of 450,000 common shares
September 13, 2016